5 March 2026 - Idebenone remains marketed in multiple countries outside the US as a treatment for Leber hereditary optic neuropathy.

Chiesi Global Rare Diseases today announced that the US FDA issued a complete response letter for idebenone for the treatment of adolescents and adults with Leber hereditary optic neuropathy.

Read Chiesi press release